Answers are grounded in this paper and cite their sources.
Adjunctive therapy with esketamine improves remission rates in treatment resistant depression, suggesting a potential new approach.
If available in one's practice area, augmenting current medication therapy with esketamine results in greater rates of remission for treatment resistant depression as compared with quetiapine¹.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: